A Randomized Controlled Trial of VE303 to Treat Hepatic Encephalopathy
Latest Information Update: 09 May 2024
At a glance
- Drugs VE 303 (Primary) ; Vancomycin
- Indications Hepatic encephalopathy
- Focus Adverse reactions; Therapeutic Use
- 10 Apr 2024 Status changed from active, no longer recruiting to completed.
- 14 Nov 2023 Results (n=18) assessing the safety and efficacy of VE303 to treat hepatic encephalopathy presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 31 Mar 2023 Status changed from recruiting to active, no longer recruiting.